RPCEC00000080已完成4 期
Impact of Recombinant Human Erythropoietin(ior EPO-CIM)in oncology pediatric patients with post chemo and /or radiotherapy.
Center of Molecular Immunology(CIM)0 个研究点目标入组 161 人开始时间: 2009年7月3日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 161
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment
入排标准
- 年龄范围
- 1 years 至 18 years(—)
- 性别
- All
入选标准
- •1.Patients that fulfill with diagnostic criteria. 2.Patients with cytological and/or histological diagnosis of cancer of any localization that are receiving chemotherapy and/or radiotherapy. 3.Patients whose parents or tutors granted written consent for participation in the study. 4.Patients aged between 1 and 18 years.
排除标准
- •1.Patients with known hypersensitivity to products derived from mammalian cells or hypersensitivity to human albumin. 2.Patients pregnant or breastfeeding. 3.Patients with active hemorrhage or hemolysis. 4.Patients with non-controlled arterial hypertension.
研究者
相似试验
已完成
4 期
Impact of Human Recombinant Erithoropoietin (ior EPOCIM) in cancer patients with post Chemo and Radiotherapy induced anemia.Anemia secondary to chemo and/or radiotherapy.RPCEC00000079Center of Molecular Immunology(CIM)338
已完成
1 期
The benefits of Erythropoietin in reducing the need for blood transfusions in patients receiving chemotherapysolid insitu tumor of the body.In situ neoplasmsD00-D09IRCT2015061822805N1Vice Chancellor for research of Tabriz University of Medical Sciences60
尚未招募
不适用
Effect of recombinant human erythropoietin administration before cardiopulmonary bypass on the development of postoperative acute kidney injury in patients undergoing valvular heart surgeryDiseases of the circulatory systemKCT0000696Asan Medical Center228
尚未招募
3 期
Erythropoietin for Perinatal asphyxiaCTRI/2018/04/013331Dr Atul Londhe
已完成
不适用
Recombinant human erythropoietin therapy in critically ill patients: a dose response studyCritically ill patients with anaemiaHaematological DisordersAnaemiaISRCTN48523317Janssen-Cilag (Greece)148
